Shares Outstanding Shares Outstanding n/a Close	66.39M
Shares Change (YoY) Shares Change (YoY) n/a Close	0.72%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	0.06%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	99.99%
Shares Floating Shares Floating n/a Close	n/a
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	41
FTD / Avg. Volume FTD / Avg. Volume n/a Close	n/a

Short Selling Information

The latest short interest is 9.13M, so 13.75% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	9.13M
Short % of Shares Out Short % of Shares Out n/a Close	13.75%
Short % of Float Short % of Float n/a Close	16.24%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	12.26

Valuation Ratios

The PE ratio is -10.31 and the forward PE ratio is -4.93. Celldex Therapeutics's PEG ratio is 0.64.

PE Ratio PE Ratio n/a Close	-10.31
Forward PE Forward PE n/a Close	-4.93
PS Ratio PS Ratio n/a Close	231.8
Forward PS Forward PS n/a Close	1.8
PB Ratio PB Ratio n/a Close	2.18
P/FCF Ratio P/FCF Ratio n/a Close	-10.19
PEG Ratio PEG Ratio n/a Close	0.64

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Celldex Therapeutics.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 18.91, with a Debt / Equity ratio of 0.01.

Current Ratio Current Ratio n/a Close	18.91
Quick Ratio Quick Ratio n/a Close	18.91
Debt / Equity Debt / Equity n/a Close	0.01
Debt / EBITDA Debt / EBITDA n/a Close	-0.02
Debt / FCF Debt / FCF n/a Close	-0.02
Interest Coverage Interest Coverage n/a Close	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$37,741.94
Profits Per Employee Profits Per Employee n/a Close	$-848,725.81
Employee Count Employee Count n/a Close	186
Asset Turnover Asset Turnover n/a Close	0.01
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	n/a
Effective Tax Rate Effective Tax Rate n/a Close	0%

Stock Price Statistics

The stock price has increased by -44.4% in the last 52 weeks. The beta is 1.14, so Celldex Therapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	1.14
52-Week Price Change 52-Week Price Change n/a Close	-44.4%
50-Day Moving Average 50-Day Moving Average n/a Close	19.05
200-Day Moving Average 200-Day Moving Average n/a Close	25.7
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	48.68
Average Volume (20 Days) Average Volume (20 Days) n/a Close	871,269

Income Statement

In the last 12 months, Celldex Therapeutics had revenue of 7.02M and earned -157.86M in profits. Earnings per share was -2.45.

Revenue Revenue n/a Close	7.02M
Gross Profit Gross Profit n/a Close	7.02M
Operating Income Operating Income n/a Close	-195.08M
Net Income Net Income n/a Close	-157.86M
EBITDA EBITDA n/a Close	-191.9M
EBIT EBIT n/a Close	-195.08M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-2.45

Full Income Statement

Balance Sheet

The company has 28.36M in cash and 3.81M in debt, giving a net cash position of 24.54M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	28.36M
Total Debt Total Debt n/a Close	3.81M
Net Cash Net Cash n/a Close	24.54M
Retained Earnings Retained Earnings n/a Close	-1.56B
Total Assets Total Assets n/a Close	739.47M
Working Capital Working Capital n/a Close	661.74M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -157.78M and capital expenditures -1.92M, giving a free cash flow of -159.7M.

Operating Cash Flow Operating Cash Flow n/a Close	-157.78M
Capital Expenditures Capital Expenditures n/a Close	-1.92M
Free Cash Flow Free Cash Flow n/a Close	-159.7M
FCF Per Share FCF Per Share n/a Close	-2.48

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -2778.89% and -2248.76%.

Gross Margin Gross Margin n/a Close	100%
Operating Margin Operating Margin n/a Close	-2778.89%
Pretax Margin Pretax Margin n/a Close	-2248.76%
Profit Margin Profit Margin n/a Close	-2248.76%
EBITDA Margin EBITDA Margin n/a Close	-2733.63%
EBIT Margin EBIT Margin n/a Close	-2778.89%
FCF Margin FCF Margin n/a Close	-2274.89%

Dividends & Yields

CLDX does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for CLDX is $46.5, which is 138.2% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$46.5
Price Target Difference Price Target Difference n/a Close	138.2%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	9

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Feb 11, 2019. It was a backward split with a ratio of 1:15.

Last Split Date Last Split Date n/a Close	Feb 11, 2019
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:15

Scores

Altman Z-Score Altman Z-Score n/a Close	17.44
Piotroski F-Score Piotroski F-Score n/a Close	2